AC Immune (NASDAQ:ACIU – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03, Zacks reports.
AC Immune Stock Performance
Shares of NASDAQ ACIU opened at $2.28 on Thursday. The company has a market cap of $225.58 million, a P/E ratio of -4.96 and a beta of 1.23. AC Immune has a 52-week low of $2.19 and a 52-week high of $4.98. The firm’s fifty day moving average is $2.64 and its two-hundred day moving average is $2.99.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of AC Immune in a research report on Friday, November 15th.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Articles
- Five stocks we like better than AC Immune
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Is a Bottom Finally Forming in Rocket Lab Stock?
- 3 Warren Buffett Stocks to Buy Now
- Gold Rally vs. Oil Surge: Where Investors Are Betting Next
- Following Congress Stock Trades
- Intel Stock Surges on New CEO – The Real Story Runs Deeper
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
